Zimmer Biomet enters $1.5 billion five-year and $1.25 billion 364-day credit facilities
Zimmer Biomet signed a new $1.5 billion five-year unsecured revolving credit agreement and a $1.25 billion 364-day unsecured revolving credit agreement, both dated June 26, 2026, with JPMorgan Chase Bank as administrative agent. The company said the borrowings will fund general corporate purposes and terminated its two prior revolving facilities dated June 27, 2025, which had no balance outstanding. The filing describes the new facilities as financing arrangements that carry covenants, including a maximum consolidated indebtedness to EBITDA ratio of 4.5 to 1.0.
Key points
- Five-year facility of $1.5 billion matures June 26, 2031, with an uncommitted feature to increase it by up to $750.0 million
- 364-day facility of $1.25 billion matures June 25, 2027
- Both agreements require a consolidated indebtedness to EBITDA ratio of no greater than 4.5 to 1.0
- Prior 2025 facilities were terminated June 26, 2026; about $0.4 million in fees were paid in cash
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.